Biomarketing strategy and tactics 101 PART III of III


The American Marketing Association defines marketing as the activity, set of institutions, and processes for creating, communicating, delivering, and exchanging offerings that have value for customers, clients, partners, and society at large. According to the Pharmaceutical Research and Manufacturers of America appropriate marketing of medicines ensures that patients have access to the products they need and that the products are used correctly for maximum patient benefit. The most important promotional tools for biopharmaceutical firms are 1) personal selling, 2) advertising, 3) public relations and publicity, and 4) web promotion. Part I of this three-part article focuses on the nature of the biopharmaceutical marketing’s four P’s, the importance of marketing strategy, the conduct of environmental analysis,  and maket segmentation. Part II delves into the processes of targeting and positioning, marketing planning, as well as biopharmaceutical branding. Part III completes the series by focusing on the push and pull promotional strategies, advertising, selling, and biopharmaceutical web and social marketing.
Requires Subscription or Fee PDF


Amgen (2011) What is ENBREL? Information for healthcare professionals,, accessed 3 October 2011.

Dogramatzis, D. (2001) Pharmaceutical Marketing: A Practical Guide. Englewood, CO.: IHS Health Group.

UCB (2011) Annual Report 2010. Brussels, Belgium: UCB, p. 16.

Federal Trade Commission (FTC; 2011) Who Cares – Sources of Information About Health Care Products and Services., accessed 3 October 2011.

U.S. Food and Drug Administration (FDA) (2011) Information for Consumers. PrescriptionDrugAdvertising/ucm072077.htm, accessed 3 October 2011.

AMGEN (2011) Annual Report 2010. Thousand Oaks, CA: Amgen, p. 48.

AMGEN (2011) Value Of Neulasta® In Treatment Planning – Information For Healthcare Professionals., accessed 3 October 2011.

Provost Peters, C. (2004) Fundamentals of the Prescription Drug Market. National Health Policy Forum Background Paper. Washington, DC: NHPF.

Arnold, M. (2009) Rx ad spend down 7.8% for first half of 2009, says TNS. Medical Marketing & Media, 16 September,, accessed 3 October 2011.

Amgen (2011) ENBREL in Rheumatoid Arthritis - Information for patients,, accessed 3 October 2011.

Arnold, M. (2009) DTC report: Between screens. Medical Marketing & Media, 44 (4): 15 March,, accessed 3 October 2011.

ELI LILLY (2011) Annual Report 2010. Indianapolis, IN: Eli Lilly, p. 15.

Evangelista, W.S., Poulin, M., Geissler, C.T., and Andrew, J. (2008) Pharma’s New U.S. Commercial Model: Promoting the science not the swag. Deloitte, /us_lshc_NewCommercialModels_072509.pdf., accessed September 2009.

CELGENE (2011) Annual Report 2010. Summit, NJ: Celgene, p. 19.

Biotechnology Industry Organization (2008) 2007-2008 Milestones. BIO: Washington, DC, 2008,

NOVARTIS Public Relations Materials on the Web., accessed 3 October 2011.

Internet World Stats (2011) World Internet Users and Population Stats., accessed 10 October 2011.

DomainTools (2011) Domain Counts & Internet Statistics., accessed 10 October 2011.

von Knoop, Carina et al. (2003) Vital Signs: E-Health in the United States. Boston, MA: Boston Consulting Group,

UCB (2011) Annual Report 2010. Brussels, Belgium: UCB, pp. 40-41.

BOEHRINGER INGELHEIM (2011) Annual Report 2010. Ingelheim, Germany: Boehringer Ingelheim, p. 122.

Dogramatzis (2010) Healthcare Biotechnology – A Practical Guide. Boca Raton, FL: CRC Press.

The present article’s figures have been modified form the author’s previously published books, references 2 and 22 above.

Unless specified by prior arrangement, the author agrees to the following terms and assurances:

  1. For myself and on behalf of the other authors listed on this work, I assign to thinkBiotech LLC the copyright* in the contribution for the full term throughout the world.
  2. I/we further give to the following assurances
    1. I am the sole author of the contribution, or, if not, I have the written authority of the other authors to transfer the copyright* to thinkBiotech LLC and give these warranties;
    2. I and (where appropriate) the other authors are entitled to transfer the copyright to thinkBiotech LLC and no one else would be entitled to prevent us from publishing the contribution;
    3. To the best of my/our knowledge, all the facts in the contribution are true and accurate;
    4. The content of the contribution is entirely original to me (and where appropriate to the other authors) or, if not, the written permission of the owner of the copyright in any material copied from elsewhere has been obtained for all media (all such permissions to be attached to the contribution as supplementary files);
    5. Nothing in the contribution is obscene or libellous;
    6. Nothing in the contribution infringes any duty of confidentiality which I/or the other authors may owe to anyone else.
    7. I and/or the other authors have obtained the appropriate clearances from my/our employer(s) or other concerned institution(s).
* Works by US government employees prepared as part of official duties are in the public domain and the authors are therefore exempt from copyright assignment.